CanSinoBIO
68818550.191.43% ( +0.71 )
CanSinoBIO (688185)
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Ad5-nCoV for Inhalation vacci...
- Open
- 50.00
- High
- 50.47
- Low
- 49.50
- Prev. Close
- 49.48
- Volume
- 16.56K
- Turnover
- 82.93M
- Avg Price
- 50.08
- Bid/Ask Ratio
- --
- Amplitude
- 1.96%
- 52wk High
- 92.70
- Volume Ratio
- 0.72
- Turnover Ratio
- 1.45%
CanSinoBIO Analyst Rating
View MoreForecast & Rating
Jun 23, 2026Price forecast
¥80.0059.39%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 21 at 12:26 AM
CanSinoBIO signs LOI with Pakistan’s AGP to explore PCV13i vaccine opportunities
- PUBT · Jul 19 at 05:08 AM
CanSino says China regulator accepts Menhycia label expansion filing to age 17
- Asian Corporate Newswire · Jun 29 at 04:21 AM
CanSinoBIO's MCV4 Receives Registration Approval in Argentina, Further Expanding International Presence in South America
- Tip Ranks · Jun 26 at 07:26 PM
CanSino Biologics, Inc. Class H (6185) Receives a Buy from UBS
- Tip Ranks · Jun 25 at 04:40 AM
CanSino Wins Argentine Approval for Menhycia Vaccine as Global Push Accelerates
- Tip Ranks · May 25 at 07:15 PM
CanSino Launches First-in-Class 24-Valent Pneumococcal Vaccine Trial
